top of page

My name is Louise. My brother Mark died February 21st, 2015, Wynyard, Saskatchewan Canada, at the age of 43.

After the sudden death of his wife, Cindy, Mark reached out for help and saw a psychiatrist for his grief. He was prescribed Abilify. After he died, papers were found on his table to join a class action lawsuit related to Abilify.

In early 2025, a $14.75 million CAD settlement was approved by courts in Quebec and Ontario for the Canadian Abilify (aripiprazole) class action. The lawsuit alleged that between 2009 and 2017, manufacturers failed to adequately warn about serious risks of compulsive behaviors, including gambling, hypersexuality, binge eating, and compulsive shopping.

Before Cindy’s death, Mark had been committed to his sobriety for years. He faithfully attended AA and worked hard to build a stable, healthy life. There was no alcohol found in his system at the time of his death. He died of fentanyl poisoning. I believe that the medication prescribed during his grief set him back on a path toward addiction. His treatment for heartbreak was medication.

Mark was the best brother anyone could ask for. He gave the biggest, warmest hugs. He was an incredible athlete—always winning crests at track meets, an outstanding baseball player. I can still picture him in the outfield, effortlessly catching a fly ball, making it look easy and natural.

I miss him every single day.

Rest in peace, Mark.

Click here to read more accounts of stolen lives.

Mark Haugan

Mark was prescribed Abilify after the sudden death of his wife.

Mark

Warning

 

The most extreme reactions to antidepressants, including suicide and violence, are more common when the dosage of an antidepressant changes or when starting or discontinuing the medication. Sometimes these reactions are caused by switching from one type of antidepressant to another. Anyone considering altering the dosage of their medication or withdrawing from it should take medical advice first from a doctor or suitably qualified practitioner. Some doctors are unaware of these issues so you may need to find one who recognises the problems and can support you.

 

Although some of our contributors and team members may work as practitioners, all of the final editorial decisions related to the content of this website have been made by non-medical people and are provided for general educational purposes only. None of the information and resources on the Antidepressant Risks website or provided in any communication constitutes or should be seen as medical, mental health, counselling, clinical or professional advice of any kind. For a full copy of our disclaimer please click here.

contact@antidepressantrisks.org

Antidepressantrisks

Antidepressant Risks CIC

Registered in England and Wales. Company No: 17402838

© Antidepressant Risks 2021-2026

United Kingdom

Disclaimer 

bottom of page